Janssen Search
Search results
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Feb 16, 2023 United States Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO, Feb. 16, 2023 -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced ...
Janssen Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy EDURANT®
Jul 28, 2023 United States Parallel application also submitted to European Medicines Agency If approved, EDURANT ® (rilpivirine) in combination with other antiretroviral therapies would offer a new HIV-1 treatment option for younger children TITUSVILLE, N ...
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
May 18, 2023 United States Launch of Multidisciplinary Council of Experts Call-to-Action During EHA Demonstrates Continued Commitment to Innovation in Multiple Myeloma RARITAN, N.J., May 18, 2023 — The Janssen Pharmaceutical Companies of Johnson & ...
Janssen Submits Type II Extension of Indication Application to the European Medicines Agency Seeking Approval of RYBREVANT®▼ (amivantamab), in combination with Lazertinib, for First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Feb 08, 2024 Belgium The submission is supported by data from the Phase 3 MARIPOSA study, showing statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutated advanced NSCLC treated with ...
Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO
Oct 16, 2023 United States Three Phase 3 RYBREVANT ® (amivantamab-vmjw) studies (MARIPOSA, MARIPOSA-2 and PAPILLON) in EGFR-mutated lung cancer achieved statistically significant and clinically meaningful progression-free survival endpoints and will ...
Janssen Receives Positive CHMP Opinion for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
Feb 24, 2023 Belgium If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European Union for first-line treatment of adult patients with metastatic castration-resistant prostate ...
Janssen Announces TREMFYA® (guselkumab) Demonstrates Significant Skin Clearance in First-of-its-Kind Prospective, Large-Scale Study Dedicated to People of Color Living with Moderate to Severe Plaque Psoriasis
Oct 20, 2023 United States VISIBLE Cohort A Week 16 topline results achieve co-primary endpoints, demonstrating the well-established efficacy and safety profile of TREMFYA ® across all skin tones In additional datasets, TREMFYA ® demonstrated rapid and ...
Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
Apr 21, 2023 Belgium Approval for AKEEGA ® is based on results from the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study that includes the largest cohort to date of BRCA1/2-positive patients with untreated metastatic castration ...
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
Dec 10, 2022 United States With nearly four years of study follow-up, all-oral, fixed duration IMBRUVICA ® + venetoclax reduced the risk of progression or death by 79 percent and demonstrated overall survival (OS) advantage versus chemoimmunotherapy NEW ...
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
Jun 03, 2023 United States CHICAGO, June 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI ® (teclistamab-cqyv), a first-in-class BCMAxCD3 ...